Sangamo Biosciences reported $0 in Debt for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Acceleron Pharma XLRN:US $ 0M 0M
Alnylam Pharmaceuticals ALNY:US $ 433.15M 241.56M
Amgen AMGN:US $ 32782M 97M
Avrobio Inc AVRO:US $ 0 0
Bayer BAYN:GR € 40372M 2493M
Biocryst Pharmaceuticals BCRX:US $ 293.66M 9.32M
Biogen BIIB:US $ 7271.1M 1.9M
Biomarin Pharmaceutical BMRN:US $ 1077.11M 0.98M
Bluebird Bio BLUE:US $ 0M 0M
GlaxoSmithKline GSK:LN 25483M 736M
Intercept Pharmaceuticals ICPT:US $ 575.82M 7.7M
IONIS PHARMACEUT IONS:US $ 1310.54M 370.12M
Karyopharm Therapeutics KPTI:US $ 301.38M 59.58M
Novartis NOVN:VX SF 35769M 2030M
Omeros OMER:US $ 312.58M 426K
Regulus Therapeutics RGLS:US $ 4.66M 0M
Sangamo Biosciences SGMO:US $ 0M 0M
Sarepta Therapeutics SRPT:US $ 1092.98M 1.88M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
Vertex Pharmaceuticals VRTX:US $ 524.92M 5.4M
Ziopharm Oncology ZIOP:US $ 0M 0M